Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.9 million.

  • Exagen's Cash from Financing Activities rose 253801.65% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 378860.57%. This contributed to the annual value of -$663000.0 for FY2024, which is 9376.41% up from last year.
  • Latest data reveals that Exagen reported Cash from Financing Activities of $2.9 million as of Q3 2025, which was up 253801.65% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Cash from Financing Activities ranged from a high of $65.1 million in Q1 2021 and a low of -$10.2 million during Q2 2023
  • Moreover, its 5-year median value for Cash from Financing Activities was -$108000.0 (2023), whereas its average is $4.1 million.
  • As far as peak fluctuations go, Exagen's Cash from Financing Activities skyrocketed by 12770980.39% in 2021, and later tumbled by 377954.55% in 2023.
  • Exagen's Cash from Financing Activities (Quarter) stood at -$213000.0 in 2021, then grew by 18.78% to -$173000.0 in 2022, then dropped by 27.17% to -$220000.0 in 2023, then grew by 1.82% to -$216000.0 in 2024, then skyrocketed by 1465.74% to $2.9 million in 2025.
  • Its Cash from Financing Activities stands at $2.9 million for Q3 2025, versus $21.9 million for Q2 2025 and -$64000.0 for Q1 2025.